Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Cullinan Therapeutics, Inc. (CGEM)

Cullinan Therapeutics Q3 net loss narrows to $49.4 million; cash $313.8 million

Positive Impact 3 of 5 earnings

Cullinan Therapeutics reported third quarter 2026 results, with a net loss of $49.4 million, down from $50.6 million a year earlier, as research and development and general and administrative expenses both declined. The company said its cash and investments of $313.8 million as of September 30, 2026 provide runway into 2029 under its current operating plan, though cash was down from $439.0 million at December 31, 2025.

Key points

  • Q3 2026 net loss was $49.4 million, compared with $50.6 million in Q3 2025; nine-month net loss was $152.8 million, compared with $169.2 million
  • Q3 2026 research and development expenses were $40.2 million, versus $42.0 million a year earlier
  • Cash, cash equivalents, investments, and interest receivable were $313.8 million at September 30, 2026, versus $439.0 million at December 31, 2025, with runway into 2029

The filing

CompanyCullinan Therapeutics, Inc. (CGEM)
Form8-K, current report
Filed with the SECNov 10, 2026, 7:06 AM ET
Accession number0001193125-26-454408

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 7:16 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.